Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Tuesday, July 12, 2016: Pharmaceutical/ Biotechnology Sector, Today's Significant News For Investors

|Includes: Juno Therapeutics (JUNO), SAGE

A summary of today's significant news for investors is provided below:

1. Shares of Sage Therapeutics (NASDAQ: SAGE) surge more than 37% after successful phase 2 trial in postpartum depression. The company has another upcoming catalyst (phase 3 trial in supra-refractory status epilepticus). Link

2. Shares of Juno Therapeutics (NASDAQ: JUNO) surge after-hours as FDA lifts hold on its clinical trial in r/r ALL. Only cyclophosphamide conditioning will be used in the trial. Link

3. Seres Therapeutics (NASDAQ: MCRB) announces collaboration with Emulate to develop novel microbiome therapies for inflammatory bowel disease and other serious conditions. Link

4. Shire gets FDA approval for Xiidra, the only approved treatment for signs and symptoms of dry eye disease. Link

5. Orbimed takes 17% stake in micro-cap Pieris Pharmaceuticals (NASDAQ: PIRS).

6. GW Pharma (NASDAQ: GWPH) announces filing of $150 million of ADS shelf.

7. Sangamo Biosciences (NASDAQ: SGMO) to participate in scientific conferences in July (watch for data release). Link

8. Exact Sciences (NASDAQ: EXAS) (cologuard for non-invasive colon cancer detection) shares were up 7% on rumor of acquisition interest from Illumina (NASDAQ: ILMN).

9. Ziopharm (NASDAQ: ZIOP) announces plans for phase 1 study of its CAR-T therapy in acute myeloid leukemia (AML). Link

10. Thinly traded Tearlabs (NASDAQ: TEAR) gets a huge price target from Rodman. Stock up 21%.

Note: To get more investment ideas like this as soon as they are published, click on my profile and hit the "Follow" button and choose the real-time alerts option.

Disclosure: I am/we are long SAGE, JUNO, MCRB, SGMO.

Additional disclosure: This article represents my own opinion and is not a substitute for professional investment advice. It does not represent solicitation to buy or sell any security. Investors should do their own research and consult their financial adviser before making any investment.